RT Journal Article
T1 The Combination of Galanin (1-15) and Escitalopram in Rats Suggests a New Strategy for Alcohol Use Disorder Comorbidity with Depression.
A1 Cantero-García, Noelia
A1 Flores-Burgess, Antonio
A1 Ladrón de Guevara-Miranda, David
A1 Serrano, Antonia
A1 García-Durán, Laura
A1 Puigcerver, Araceli
A1 Fuxe, Kjell
A1 Narváez, José Ángel
A1 Santín, Luis Javier
A1 Díaz-Cabiale, Zaida
A1 Millón, Carmelo
K1 Galanin (1–15)
K1 alcohol
K1 depression
K1 escitalopram
AB Alcohol use disorder (AUD) is highly prevalent, and over 50% of AUD patients also suffer major depressive disorders. Selective 5-HT reuptake inhibitors (SSRIs) can reduce rodent ethanol drinking but exert modest clinical efficacy in alcoholic individuals. Finding new pharmacological strategies that could modulate alcohol consumption and depression is necessary. We have analyzed the effect of Galanin (1-15) [GAL(1-15)] on escitalopram (ESC)-mediated effect in alcohol consumption using the alcohol self-administration test, the nuclei involved in the effect, and whether GAL(1-15) + ESC modulated the response in despair or anxiety tests in animals under chronic alcohol intake. GAL(1-15) + ESC combination substantially reduced alcohol intake in the alcohol self-administration test and, moreover, enhanced the reduction of reward capacity of ESC on different reinforcers such as sucrose or saccharine. GAL(1-15) + ESC coadministration significantly decreases the number of C-Fos-IR TH cell bodies in the VTA, and PCA analysis suggests that one functional network, including VTA, RMTg and DR, is involved in these effects. Significantly in rats with chronic alcohol consumption, GAL(1-15) reversed adverse ESC-mediated effects in the depression-related behavioural test and forced swimming test. The results open up the possibility of using GAL(1-15) in combination with the SSRI Escitalopram as a novel strategy in AUD comorbidity with depression.
SN 2227-9059
YR 2022
FD 2022-02-09
LK http://hdl.handle.net/10668/20818
UL http://hdl.handle.net/10668/20818
LA en
DS RISalud
RD Apr 5, 2025